Cancer/testis (CT) antigens: Potential targets for immunotherapy Journal Article
| Authors: | Caballero, O. L.; Chen, Y. T. |
| Article Title: | Cancer/testis (CT) antigens: Potential targets for immunotherapy |
| Abstract: | Cancer/testis (CT) antigens are protein antigens with normal expression restricted to adult testicular germ cells, and yet are aberrantly activated and expressed in a proportion of various types of human cancer. At least a subset of this group of antigens has been found to elicit spontaneous humoral and cell-mediated immune responses in cancer patients, raising the possibility that these antigens could be cancer vaccine targets. More than 100 CT antigen genes have been reported in the literature, with approximately 30 being members of multigene families on the X chromosome, so-called CT-X genes. Most CT-X genes are expressed at the spermatogonia stage of spermatogenesis, and their functions are mostly unknown. In cancer, the frequency of CT antigen expression is highly variable among different tumor types, but is more often expressed in high-grade late-stage cases in general. Cancer vaccine trials based on CT antigens MAGE-A3 and NY-ESO-1 are currently ongoing, and these antigens may also play a role in antigen-specific adoptive T-cell transfer and in the immunomodulation approach of cancer therapy. (Cancer Sci 2009). © 2009 Japanese Cancer Association. |
| Keywords: | protein expression; unclassified drug; overall survival; histone deacetylase inhibitor; clinical trial; review; liver cell carcinoma; nonhuman; disease free survival; pancreas cancer; protein localization; antigen expression; ipilimumab; cancer immunotherapy; melanoma; metastasis; multiple myeloma; imiquimod; etoposide; lung non small cell cancer; tumor regression; gene expression regulation; cancer vaccine; minimal residual disease; tumor recurrence; cancer testis antigen; ny eso 1 antigen; immunogenicity; montanide isa 51; antibody response; ovary carcinoma; adoptive transfer; x chromosome; 5 aza 2' deoxycytidine; dna vaccine; immunological adjuvant; iscom; mage a3 protein vaccine; melan a; melanoma antigen; melanoma antigen a1; melanoma antigen a10; melanoma antigen a2; melanoma antigen a3; melanoma antigen a4; melanoma antigen c1; ny eso 1 protein vaccine; pullulan; immunomodulation |
| Journal Title: | Cancer Science |
| Volume: | 100 |
| Issue: | 11 |
| ISSN: | 1347-9032 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2009-11-01 |
| Start Page: | 2014 |
| End Page: | 2021 |
| Language: | English |
| DOI: | 10.1111/j.1349-7006.2009.01303.x |
| PROVIDER: | scopus |
| PUBMED: | 19719775 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 25" - "Export Date: 30 November 2010" - "CODEN: CSACC" - "Source: Scopus" |
